Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Houming Zhao

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Chinese Medical Journal|June 29, 2026
Reclassifying renal cell carcinoma with pathologic lymph node metastasis: An approach to refining prognostic stratification in patients with AJCC III and IV stagesXu Bai, Tongyu Jia, Houming Zhao, et al.
Signal Transduction and Targeted Therapy|October 3, 2024
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 studyLiangyou Gu, Cheng Peng, Qiyang Liang, et al.
Academic Radiology|February 18, 2026
MRI-Based Habitat Radiomics for Predicting Postoperative Recurrence in Nonmetastatic Clear Cell Renal Cell CarcinomaSicheng Yi, Tongyu Jia, Xu Bai, et al.
Medcomm|April 9, 2026
Neoadjuvant Toripalimab Plus Axitinib for Nonmetastatic Clear Cell Renal Cell Carcinoma With Tumor Thrombus: A Combined Analysis of Two Phase II Clinical TrialsCheng Peng, Zhuolong Wu, Yaohui Wang, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Chinese Medical Journal|June 29, 2026
Reclassifying renal cell carcinoma with pathologic lymph node metastasis: An approach to refining prognostic stratification in patients with AJCC III and IV stagesXu Bai, Tongyu Jia, Houming Zhao, et al.
Signal Transduction and Targeted Therapy|October 3, 2024
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 studyLiangyou Gu, Cheng Peng, Qiyang Liang, et al.
Academic Radiology|February 18, 2026
MRI-Based Habitat Radiomics for Predicting Postoperative Recurrence in Nonmetastatic Clear Cell Renal Cell CarcinomaSicheng Yi, Tongyu Jia, Xu Bai, et al.
Medcomm|April 9, 2026
Neoadjuvant Toripalimab Plus Axitinib for Nonmetastatic Clear Cell Renal Cell Carcinoma With Tumor Thrombus: A Combined Analysis of Two Phase II Clinical TrialsCheng Peng, Zhuolong Wu, Yaohui Wang, et al.
Pageof 2